KR102463782B1 - A whitening composition and its manufacturing method by bio-renovation of Ligustrum Janponicum Extract - Google Patents
A whitening composition and its manufacturing method by bio-renovation of Ligustrum Janponicum Extract Download PDFInfo
- Publication number
- KR102463782B1 KR102463782B1 KR1020200187046A KR20200187046A KR102463782B1 KR 102463782 B1 KR102463782 B1 KR 102463782B1 KR 1020200187046 A KR1020200187046 A KR 1020200187046A KR 20200187046 A KR20200187046 A KR 20200187046A KR 102463782 B1 KR102463782 B1 KR 102463782B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- biorenovation
- tree
- whitening
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 58
- 230000002087 whitening effect Effects 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 238000009418 renovation Methods 0.000 title claims description 3
- 241000735234 Ligustrum Species 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 22
- 244000005700 microbiome Species 0.000 claims abstract description 20
- 241000193744 Bacillus amyloliquefaciens Species 0.000 claims abstract description 18
- 239000008188 pellet Substances 0.000 claims abstract description 18
- 230000000813 microbial effect Effects 0.000 claims abstract description 16
- 238000006243 chemical reaction Methods 0.000 claims abstract description 15
- 238000012258 culturing Methods 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 239000000872 buffer Substances 0.000 claims description 9
- 239000007795 chemical reaction product Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 14
- 239000004480 active ingredient Substances 0.000 abstract description 13
- 201000001441 melanoma Diseases 0.000 abstract description 13
- 239000000376 reactant Substances 0.000 abstract description 13
- 230000004913 activation Effects 0.000 abstract description 6
- 229930014626 natural product Natural products 0.000 abstract description 5
- 230000016571 aggressive behavior Effects 0.000 abstract description 3
- 230000006907 apoptotic process Effects 0.000 abstract description 2
- 235000015701 Artemisia arbuscula Nutrition 0.000 abstract 1
- 235000002657 Artemisia tridentata Nutrition 0.000 abstract 1
- 240000006891 Artemisia vulgaris Species 0.000 abstract 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 1
- 230000009088 enzymatic function Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 25
- 102000003425 Tyrosinase Human genes 0.000 description 24
- 108060008724 Tyrosinase Proteins 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 230000008099 melanin synthesis Effects 0.000 description 22
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 14
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 12
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 9
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 7
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 7
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 7
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 5
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 5
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 5
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000003656 tris buffered saline Substances 0.000 description 5
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 240000000249 Morus alba Species 0.000 description 4
- 235000008708 Morus alba Nutrition 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 239000012083 RIPA buffer Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- RIXNFYQZWDGQAE-DFHVBEEKSA-N (4as,6ar,6as,6br,8ar,10s,12ar,14bs)-10-acetyloxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C([C@H]1C2=CC[C@H]34)C(C)(C)CC[C@]1(C(O)=O)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)C)C1(C)C RIXNFYQZWDGQAE-DFHVBEEKSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 2
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- 244000167230 Lonicera japonica Species 0.000 description 2
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 2
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 2
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 2
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- -1 skin Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 2
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 2
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001356719 Burmannia cryptopetala Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- BGHNZAWRRWLKPO-UHFFFAOYSA-N Ginsenoside F1 Natural products CC(=C)CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C BGHNZAWRRWLKPO-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000321384 Gymnadenia rhellicani Species 0.000 description 1
- 241000264002 Kimberleytrachia serrata Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000018022 Liparis nervosa Species 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001453763 Plagiogyria japonica Species 0.000 description 1
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 240000008841 Utricularia uliginosa Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- XNGXWSFSJIQMNC-FIYORUNESA-N ginsenoside F1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@H](O)[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XNGXWSFSJIQMNC-FIYORUNESA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 231100001068 severe skin irritation Toxicity 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 광나무 추출물의 바이오리노베이션에 의한 미백 조성물 및 이의 제조 방법에 관한 것으로, 천연물인 광나무의 유효성분을 미생물의 효소적 기능을 이용하여 B16F10 흑색종 세포의 활성화를 억제(사멸, 공격성 완화 포함)시키는 반응물을 생성함으로써 피부의 안정성을 높이고 부작용을 감소시키면서 피부 미백에 도움을 주는 것을 목적으로 한다.
본 발명에 의한 광나무 추출물의 바이오리노베이션에 의한 미백 조성물은, 미생물인 바실러스 아미로리쿼파시엔스(Bacillus amyloliquefaciens)와 광나무 추출물의 혼합 반응으로 이루어진다.
본 발명에 의한 광나무 추출물의 바이오리노베이션에 의한 미백 조성물의 제조 방법은, 광나무 추출물을 제조하는 제1단계와; 미생물로 바실러스 아미로리쿼파시엔스(Bacillus amyloliquefaciens)를 선정하고 배양한 후 원심분리하여 미생물 펠렛을 수득하는 제2단계와; 상기 제2단계에서 수득한 미생물 펠렛과 상기 제1단계에서 제조한 광나무 추출물을 혼합 반응시키는 제3단계를 포함하고, 상기 제1단계는 광나무의 꽃과 잎을 에탄올로 주정추출한 후 감압 농축을 통해 광나무 추출물을 추출한다.The present invention relates to a whitening composition by biorenovation of an extract of Gwangju and a method for preparing the same, and inhibits the activation of B16F10 melanoma cells (including apoptosis and aggression relief) by using an active ingredient of a natural product, a natural product, the enzymatic function of a microorganism. It aims to help skin whitening while increasing the stability of the skin and reducing side effects by generating a reactant.
The composition for whitening by biorenovation of the extract of Gwangju according to the present invention consists of a mixed reaction of the microorganism, Bacillus amyloliquefaciens , and the extract of Gwangju.
According to the present invention, a method for preparing a whitening composition by biorenovation of a Kwangnam tree extract comprises: a first step of preparing the Kwangno tree extract; A second step of selecting and culturing Bacillus amyloliquefaciens as a microorganism and then centrifuging to obtain a microbial pellet; and a third step of mixing and reacting the microbial pellets obtained in the second step with the Kwangnam tree extract prepared in the first step, wherein the first step is extracting the flowers and leaves of Kwangnam tree with ethanol and then concentration under reduced pressure. Extract the sagebrush extract.
Description
본 발명은 광나무를 이용한 미백 조성물에 관한 것으로, 더욱 상세하게는 천연물인 광나무의 유효성분으로부터 피부 미백에 효과적이면서 피부의 안정성을 높이고 부작용을 감소시키는 광나무 추출물의 바이오리노베이션에 의한 미백 조성물 및 이의 제조 방법에 관한 것이다.The present invention relates to a whitening composition using Gwang tree, and more particularly, a whitening composition by biorenovation of Gwang tree extract, which is effective for skin whitening from the active ingredient of Gwang tree, which is a natural product, while increasing skin stability and reducing side effects, and a method for manufacturing the same is about
이 부분은 본 출원 내용과 관련된 배경 정보를 제공할 뿐 반드시 선행기술이 되는 것은 아니다.This section provides background information related to the subject matter of the present application and is not necessarily prior art.
사람의 피부색은 노화, 자외선, 스트레스 등 다양한 요인에 의해 변하게 되며, 피부 내부의 멜라닌(melanin) 농도와 분포에 따라 결정되는데, 유전적인 요인 외에도, 태양 자외선이나 피로, 스트레스 등의 환경적 또는 생리적 조건에 의해서도 영향을 받는다. Human skin color is changed by various factors such as aging, UV rays, and stress, and it is determined by the concentration and distribution of melanin inside the skin. is also affected by
멜라닌 세포(melanocyte)는 모발색과 피부색을 결정하는 페놀류의 생체고분자 물질로 검은 단백질의 복합체인 멜라닌(melanin)을 합성하고 분비하여, 자외선에 의한 피부손상을 막아줄 뿐 아니라 독성 약물의 흡수 등 여러 중요한 작용을 수행한다.Melanocytes are phenolic biopolymers that determine hair color and skin color. They synthesize and secrete melanin, a complex of black protein, to prevent skin damage caused by UV rays, as well as to absorb toxic drugs. perform an important role.
멜라닌은 다양한 형태 및 과정으로 피부에 흡수되어 피부 기저층에 존재하며, 자외선 및 외부 손상으로부터 피부를 보호하는 역할을 한다. 특히 자외선은 피부 면역계의 구성 요소를 활성화하여 염증 매개체를 방출하는 각질형성 세포 (keratinocyte) 및 기타 세포의 직접 활성화 등 많은 기전을 통해 염증 반응을 유발할 수 있다. 자외선으로 유도된 DNA 손상은 p53이 POMC (pro-opiomelanocortin) 유전자의 프로모터에 대한 결합을 활성화하여 α-MSH (melanocyte-stimulating hormones)를 생성하며, 생성된 α-MSH는 멜라닌 세포로 신호를 보내는 역할을 하는 MC1R(melanocortin 1 receptor)와 결합하여 cAMP(cyclic adenosine monophosphosphate) 생산을 자극하고, 증가된 cAMP는 PKA (protein kinase A)를 활성화하여 cAMP 반응 요소인 CREB(cAMP response element-binding protein) 단백질을 인산화한다. CREB는 MITF (microphthalmia-associated transcription factor)의 발현을 포함하여 다양한 유전자의 발현을 조절하는 전사 인자이다. MITF는 멜라닌 생성 효소인 TRP(tyrosinase-related protein)-1, 2, 및 티로시나제(tyrosinase)의 발현을 조절한다. 그 중 tyrosinase 효소로부터 시작되는 멜라닌 생성은 티로시나제(tyrosinase) 효소가 도파(DOPA)(3, 4-dihydroxy phenylalanine)를 거쳐 도파퀴논(DOPA-quinone)으로 변환되며, 이것이 효소반응과 자동 산화 반응으로 DOPA-chrome을 거쳐 멜라닌이 형성된다. Melanin is absorbed into the skin in various forms and processes and is present in the basal layer of the skin, and serves to protect the skin from UV rays and external damage. In particular, UV rays can trigger an inflammatory response through many mechanisms, including direct activation of keratinocytes and other cells that activate components of the skin immune system to release inflammatory mediators. UV-induced DNA damage activates the binding of p53 to the promoter of the POMC (pro-opiomelanocortin) gene to generate α-MSH (melanocyte-stimulating hormones), and the produced α-MSH serves to send a signal to melanocytes. Stimulates cAMP (cyclic adenosine monophosphosphate) production by binding to MC1R (
이와 같은 멜라닌의 합성이 피부 내에서 과도하게 일어나면, 피부 톤을 어둡게 하고, 기미, 주근깨 등을 발생시키기기도 한다. 따라서, 피부내의 멜라닌 색소의 합성을 저해시키면, 피부 톤을 밝게 하여 피부 미백을 실현할 수 있을 뿐만 아니라 자외선, 호르몬 및 유전적인 원인에 기인하여 발생하는 기미, 주근깨 등의 피부 과색소 침착증을 개선시킬 수 있다. 따라서, 종래에는 하이드로퀴논(hydroquinone)이나 아스콜빈산(ascorbic acid), 코지산(kojic acid), 글루타티온(glutathione)과 같은 티로시나제에 대해 저해 활성을 갖는 물질을 연고, 에센스 등의 화장료에 배합함으로써 피부 미백을 실현하거나, 기미, 주근깨 등의 피부 과색소 침착증을 개선하였다. 그러나, 하이드로퀴논은 소정의 미백효과를 발휘하지만, 피부 자극성이 심하여 배합량을 극소량으로 제한해야 하는 문제점이 있고, 아스콜빈산은 산화되기 쉬워 이를 배합한 화장료는 변색, 변취되는 등의 문제가 발생하는 단점이 있다. 또한, 글루타티온, 시스테인 등의 티올계 반응물은 특유의 불쾌한 냄새를 가질 뿐만 아니라 경피흡수에도 문제점이 있고, 이들의 배당체 및 유도체들도 극성이 높으므로 화장료의 배합 성분으로 사용하기는 어렵다. When the synthesis of melanin occurs excessively in the skin, the skin tone is darkened, and spots, freckles, and the like occur. Therefore, by inhibiting the synthesis of melanin in the skin, it is possible not only to realize skin whitening by brightening the skin tone, but also to improve skin hyperpigmentation such as spots and freckles caused by ultraviolet rays, hormones, and genetic causes. have. Therefore, in the prior art, a substance having inhibitory activity against tyrosinase, such as hydroquinone, ascorbic acid, kojic acid, and glutathione, is mixed with cosmetics such as ointments and essences to the skin. Whitening was realized or skin hyperpigmentation such as spots and freckles was improved. However, hydroquinone exhibits a certain whitening effect, but there is a problem that the blending amount must be limited to a very small amount due to severe skin irritation. There is this. In addition, thiol-based reactants such as glutathione and cysteine not only have a characteristic unpleasant odor, but also have a problem in transdermal absorption, and their glycosides and derivatives are also highly polar, so it is difficult to use them as ingredients in cosmetics.
피부 미백을 위한 특허문헌으로 등록특허 제10-1326690호는 진세노사이드 F1(20-O-β-D-글루코피라노실-20(S)-프로토파낙사트리올)을 유효 성분으로 함유하는 피부 미백용 화장료 조성물이며, 등록특허 제10-2010235호는 흑난초 (Liparis nervosa (Thunb.) Lindl.), 섬꿩고사리 (Plagiogyria japonica Nakai), 버어먼초 (Burmanniacryptopetala Makino) 및 자주땅귀개 (Utricularia yakusimensis Masam.)의 혼합물로부터 추출된 혼합추출물을 함유하는 피부보습 및 피부미백 기능을 갖는 화장료 조성물이고, 등록특허 제10-0894714호는 물, 알코올 또는 이들의 혼합물로 추출되며, 피부 미백 활성을 가지는 백모사(Humata tyermanni Moore) 추출물을 유효성분으로 포함하는 피부미백용 화장료 조성물이며, 지금까지 광나무를 미백을 위한 재료로 사용하지는 않았다.As a patent document for skin whitening, Patent Registration No. 10-1326690 discloses skin containing ginsenoside F1 (20-O-β-D-glucopyranosyl-20(S)-protophanaxatriol) as an active ingredient. It is a cosmetic composition for whitening, and Patent Registration No. 10-2010235 discloses black orchid (Liparis nervosa (Thunb.) Lindl.), pheasant fern (Plagiogyria japonica Nakai), Burmannia cryptopetala Makino and Utricularia yakusimensis Masam. It is a cosmetic composition having a skin moisturizing and skin whitening function containing a mixed extract extracted from a mixture of tyermanni Moore) extract as an active ingredient.
본 발명은 전술한 바와 같은 문제점을 해결하기 위한 것으로, 미생물의 반응을 통해 천연물인 광나무의 유효성분으로부터 B16F10 흑색종 세포의 활성화를 억제(사멸, 공격성 완화 포함)시키고 멜라닌 합성을 저해하는 화합물을 생성함으로써 피부의 안정성을 높이면서 부작용을 감소시키는 광나무 추출물의 바이오리노베이션에 의한 미백 조성물 및 이의 제조 방법을 제공하려는데 그 목적이 있다. The present invention is to solve the above-mentioned problems, and inhibits the activation of B16F10 melanoma cells from the active ingredient of the natural product, Gwangnae, through the reaction of microorganisms (including apoptosis, alleviation of aggression) and produces a compound that inhibits melanin synthesis An object of the present invention is to provide a whitening composition by biorenovation of Kwangnam extract that increases skin stability and reduces side effects, and a method for preparing the same.
본 발명에 의한 광나무 추출물의 바이오리노베이션에 의한 미백 조성물은, 미생물인 바실러스 아미로리쿼파시엔스(Bacillus amyloliquefaciens)와 광나무 추출물의 혼합 반응으로 이루어진 것을 특징으로 한다.The whitening composition by biorenovation of the Kwangnam tree extract according to the present invention is characterized in that it consists of a mixed reaction of the microorganism Bacillus amyloliquefaciens and the Kwangno tree extract.
본 발명에 의한 광나무 추출물의 바이오리노베이션에 의한 미백 조성물의 제조 방법은, 광나무 추출물을 제조하는 제1단계와; 미생물로 바실러스 아미로리쿼파시엔스(Bacillus amyloliquefaciens)를 선정하고 배양한 후 원심분리하여 미생물 펠렛을 수득하는 제2단계와; 상기 제2단계에서 수득한 미생물 펠렛과 상기 제1단계에서 제조한 광나무 추출물의 반응으로 광나무 추출물의 유효성분을 통해 흑색종 세포의 활성화를 억제시킬 수 있도록 생물전환시키는 제3단계를 포함하고, 상기 제3단계는 상기 미생물 펠렛을 PG 버퍼로 세척하여 PG 버퍼 현탁액으로 현탁시킨 후 상기 광나무 추출물과 반응시킨다.According to the present invention, a method for preparing a whitening composition by biorenovation of a Kwangnam tree extract comprises: a first step of preparing the Kwangno tree extract; A second step of selecting and culturing Bacillus amyloliquefaciens as a microorganism and then centrifuging to obtain a microbial pellet; A third step of bioconversion to inhibit the activation of melanoma cells through the reaction of the microbial pellet obtained in the second step and the Kwangnamu extract prepared in the first step through the active ingredient of the Kwangnae extract, In the third step, the microbial pellet is washed with PG buffer, suspended in a PG buffer suspension, and then reacted with the Kwangnam tree extract.
본 발명에 의한 광나무 추출물의 바이오리노베이션에 의한 미백 조성물 및 이의 제조 방법에 의하면, 미백을 위하여 사용하지 않던 광나무의 유효성분을 미생물과의 반응을 통해 B16F10 흑색종 세포의 활성화를 억제(사멸, 공격성 완화 포함)시키고 멜라닌 합성을 저해하는 화합물을 생성함으로써 피부 미백에 도움을 주는 한편 천연물로서 피부의 안정성을 높이고 부작용을 감소시키는 효과가 있다.According to the whitening composition by biorenovation of the Gwang tree extract according to the present invention and the method for preparing the same, the active ingredient of Gwangmyeon, which was not used for whitening, inhibits the activation of B16F10 melanoma cells through the reaction with microorganisms (death, alleviation of aggression) ) and produces a compound that inhibits melanin synthesis, thereby helping skin whitening, and as a natural product, it has the effect of increasing the stability of the skin and reducing side effects.
따라서, 스킨, 로션, 크림, 에센스, 팩, 폼 클렌징 등 화장품이나 외용 연고와 같은 약품 등의 피부미백용 조성물에 첨가되어 피부 트러블없이 사용할 수 있어 자외선에 노출되어도 피부 미백이 오랫동안 유지되는 효과를 갖는다.Therefore, it can be used without skin trouble by being added to skin whitening compositions such as cosmetics such as skin, lotion, cream, essence, pack, foam cleansing, etc. or medicines such as ointment for external use. .
도 1은 본 발명에 의한 광나무 추출물의 바이오리노베이션에 의한 미백 조성물 제조 방법의 공정도.
도 2는 일반적인 광나무와 본 발명에 의한 광나무 추출물의 리노베이션 반응물 및 바실러스 아미로리쿼파시엔스의 HPLC 크로마토그램의 그래프.
도 3 내지 도 9는 본 발명의 실시예에 따른 광나무 추출물의 바이오리노베이션에 의한 미백 조성물의 테스트 결과를 보인 것으로,
도 3은 B16F10 세포 생존율을 보인 그래프이고,
도 4는 멜라닌(Melanin) 내용물의 양을 보인 그래프이며,
도 5는 티로시나아제(tyrosinase) 활성도 테스트 결과를 보인 그래프이고,
도 6 내지 도 9는 본 발명의 광나무 추출물의 바이오리노베이션에 의한 미백 조성물의 웨스턴 블롯(Western blot) 분석 결과를 보인 영상이다.1 is a process diagram of a method for preparing a whitening composition by biorenovation of an extract of Gwangju tree according to the present invention.
Figure 2 is a graph of the HPLC chromatogram of the general Kwangnae and the renovation reaction of the Kwangnae extract according to the present invention and Bacillus amyloliquefaciens.
3 to 9 show the test results of the whitening composition by biorenovation of Gwangnam extract according to an embodiment of the present invention,
3 is a graph showing the B16F10 cell viability,
Figure 4 is a graph showing the amount of melanin (Melanin) content,
Figure 5 is a graph showing the tyrosinase (tyrosinase) activity test results,
6 to 9 are images showing the results of Western blot analysis of the whitening composition by biorenovation of the Gwangnam tree extract of the present invention.
하기에서 본 발명을 설명함에 있어, 관련된 공지 기능 또는 구성에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우에는 그 상세한 설명은 생략할 것이다. 그리고 후술되는 용어들은 본 발명에서의 기능을 고려하여 정의된 용어들로서 이는 사용자, 운용자의 의도 또는 관례 등에 따라 달라질 수 있다. 그러므로 그 정의는 본 명세서 전반에 걸친 내용을 토대로 내려져야 할 것이다.In the following description of the present invention, if it is determined that a detailed description of a related known function or configuration may unnecessarily obscure the gist of the present invention, the detailed description thereof will be omitted. In addition, the terms described below are terms defined in consideration of functions in the present invention, which may vary according to intentions or customs of users and operators. Therefore, the definition should be made based on the content throughout this specification.
본 발명에 의한 광나무 추출물의 바이오리노베이션에 의한 미백 조성물은, 미생물인 바실러스 아미로리쿼파시엔스(Bacillus amyloliquefaciens)에 의한 바이오리노베이션(Biorenovation) 생물전환기법을 통해 광나무의 유효성분으로부터 B16F10 흑색종 세포의 활성화를 억제시킬 수 있는 항산화 특성이 우수한 바이오리노베이션 반응물로 생성된 것이다.The whitening composition by biorenovation of the Gwangnam extract according to the present invention, the activation of B16F10 melanoma cells from the active ingredient of Gwangju through the biorenovation bioconversion technique by the microorganism Bacillus amyloliquefaciens It is produced as a biorenovation reactant with excellent antioxidant properties that can inhibit
1. 광나무 추출물.1. Guangxin extract.
광나무는 물푸레나무과 쥐똥나무에 속하는 식물로서, 전남, 경남의 해안, 제주, 섬지방, 일본과 대만 등지에서 분포하는 상록활엽교목으로, 정목 또는 여정목이라고도 부르며, 열매를 여정실이라고 한다. 또한, 잎에는 시린진(syringin), 과피와 과육에 우르솔산(ursolic acid), 올레오놀산(oleanolic acid), 아세틸 올레오놀산(acetyl-oleanolic acid) 등의 성분이 함유되어 있다고 알려져 있다. 광나무 잎은 성질이 평하고 독이 없으며, 시력을 좋게 하고 통증완화, 구내염, 치주염, 급성세균성 이질, 악성종양, 화상 등에 효과가 있다고 보고되어 있다. 지금까지는 광나무의 미백 효과에 대한 연구는 아직 알려지지 않았으며, 본 발명을 통해 광나무의 유효성분(syringin)으로부터 미백이 가능한 조성물을 얻고자 하는 것이다.Gwangnam is an evergreen broad-leaved arboreous tree distributed in Jeollanam-do, Gyeongsangnam-do coast, Jeju, island regions, Japan and Taiwan as a plant belonging to the oleaceae family. In addition, it is known that the leaves contain syringin, and components such as ursolic acid, oleanolic acid, and acetyl-oleanolic acid are contained in the peel and flesh. It has been reported that the leaves of Gwangnam are smooth in nature and non-toxic, improve eyesight, and are effective in relieving pain, stomatitis, periodontitis, acute bacterial dysentery, malignant tumors, and burns. Until now, research on the whitening effect of Gwangnam is not yet known, and it is an object to obtain a composition capable of whitening from the active ingredient (syringin) of Gwangmyeon through the present invention.
2. 바실러스 아미로리쿼파시엔스(Bacillus amyloliquefaciens).2. Bacillus amyloliquefaciens ( Bacillus amyloliquefaciens ).
미생물 리노베이션을 위한 미생물로는 바실러스 아미로리쿼파시엔스(Bacillus amyloliquefaciens)를 선정하였다.As a microorganism for microbial innovation, Bacillus amyloliquefaciens was selected.
바실러스 아미로리쿼파시엔스(Bacillus amyloliquefaciens)는 예를 들어 제주 전통 젓갈에 존재하는 미생물을 대상으로 탐색하였으며, 그 중 제주콩 재래간장에서 분리한 바실러스 아미로리쿼파시엔스(Bacillus amyloliquefaciens)를 선정하였다.Bacillus amyloliquefaciens ( Bacillus amyloliquefaciens ) was searched for microorganisms existing in Jeju traditional salted fish, for example, and among them, Bacillus amyloliquefaciens isolated from Jeju soybean soy sauce was selected.
즉, 본 발명은 제주도에서 많은 양이 재배되고 있는 광나무와 제주 전통 젓갈을 이용하는 점에서 지방자치단체의 특산품 활용으로 지자체의 홍보와 함께 경제 활성화에 도움을 줄 수 있다.That is, the present invention can help to promote the economy and promote the local government by utilizing the local government's special products in that the present invention uses Gwangnam, which is cultivated in large quantities in Jeju Island, and Jeju's traditional salted fish.
본 발명에 의한 광나무 추출물의 바이오리노베이션에 의한 미백 조성물의 제조 방법의 전체 공정은 광나무 추출물 제조 - 미생물 선정 및 배양 - 바이오리노베이션 - 원심분리/여과 - 동결건조를 포함하며 각 공정은 다음과 같다(도 1 참조).The overall process of the method for producing a whitening composition by biorenovation of a mulberry extract according to the present invention includes preparation of a mulberry extract - selection and culture of microorganisms - biorenovation - centrifugation / filtration - freeze-drying, and each process is as follows (Fig. see 1).
1. 광나무 추출물 제조.1. Manufacture of extracts from mulberry.
광나무 추출물은 주정추출을 통해 제조되며 그 공정은 주정 추출 - 여과 - 감압농축 - 동결건조이며 구체적인 공정은 다음과 같다.Gwangnam tree extract is manufactured through alcohol extraction, and the process is alcohol extraction - filtration - concentration under reduced pressure - freeze-drying The specific process is as follows.
가. 주정 추출.go. spirit extraction.
광나무의 잎(작은 크기로 분쇄 가능) 300g에 대하여 에탄올(바람직하게 70% Ethanol) 0.9~1.1 L의 양을 이용하여 주정추출한다. Extract alcohol using 0.9-1.1 L of ethanol (preferably 70% Ethanol) with respect to 300 g of leaves (can be pulverized into small sizes).
주정추출의 조건은 57~63℃, 2시간 40분~3시간 20분, 바람직하게 60℃, 3시간이다.Conditions for ethanol extraction are 57-63°C, 2
나. 여과.me. percolation.
주정추출된 추출물은 고형물을 포함하고 있으며, 고형물을 예를 들어, 여과지(paper filter)로 여과한다.The alcohol-extracted extract contains a solid, and the solid is filtered with, for example, a filter paper (paper filter).
다. 농축(감압 농축).All. Concentration (vacuum concentration).
여과 공정을 거친 추출물의 유효성분 농도를 높이기 위하여 추출물을 농축, 바람직하게 감압 농축(통상의 감압 농축 조건 안에서 자유롭게 실시 가능하므로 감압 농축의 조건을 구체적인 수치로 한정하지 아니한다)하고 이 과정에서 에탄올을 제거한다.In order to increase the concentration of the active ingredient of the extract that has undergone the filtration process, the extract is concentrated, preferably concentrated under reduced pressure (it can be freely carried out under normal reduced pressure concentration conditions, so the conditions for concentration under reduced pressure are not limited to specific values), and ethanol is removed in this process do.
라. 동결 건조.la. freeze-dried.
감압 농축을 거친 농축액을 예를 들어 영하 110℃로 동결 건조하여 보관할 수 있으며, 동결 건조 공정은 필요에 따라 선택되는 것이다.The concentrated solution subjected to reduced pressure concentration may be stored by freeze-drying at, for example, minus 110° C., and the freeze-drying process is selected as necessary.
이상의 주정 추출 공정은 광나무의 유효성분을 파괴하지 않고 추출하는데 최적의 공정이다.The above alcohol extraction process is the optimal process for extraction without destroying the active ingredients of the mulberry tree.
2. 미생물 선정 및 배양.2. Microbial selection and culture.
미생물로 선정한 바실러스 아미로리쿼파시엔스를 Nutrient broth(Beef extract 3.0 g/L, Peptone 5.0 g/L)에서 최적 생육 조건에 맞추어 18시간~22시간, 바람직하게 20시간 배양하였다. 20시간 배양 후, 미생물을 4,800~5,200rpm의 속도, 3~5℃, 8분~12분간, 바람직하게 5,000 rpm, 4℃, 10분 동안 원심분리하여 미생물 펠렛(pellet)을 수득한다. Bacillus amyloliquefaciens selected as a microorganism was cultured in Nutrient broth (Beef extract 3.0 g/L, Peptone 5.0 g/L) for 18 hours to 22 hours, preferably for 20 hours according to optimal growth conditions. After culturing for 20 hours, the microorganisms are centrifuged at a speed of 4,800 to 5,200 rpm, 3 to 5° C., 8 minutes to 12 minutes, preferably 5,000 rpm, 4° C., for 10 minutes to obtain a microbial pellet.
3. 바이오리노베이션(생물전환 반응).3. Biorenovation (biotransformation reaction).
가. 반응 합성.go. reaction synthesis.
수득한 미생물 펠렛을 PG 버퍼(50 mM phosphate pH 7.2 및 2% 글리세롤)로 세척하여, PG 버퍼(buffer) 5ml에 현탁시켰다(현탁하는 이유는 미생물을 배양하는 배지에 포함된 이물질을 제거하여 깨끗한 상태에서 반응을 유도하기 위한 것이며, 조성 중 글리세롤의 농도를 정확하게 하기 위한 것이다). 이후 현탁액과 광나무 추출물을 혼합{광나무 추출물 : 미생물 펠렛 : PG 버퍼 = 1 : 9~11 : 45~55의 중량비, 바람직하게 1 : 10 : 50의 중량비로 혼합}하여 27~33℃에서 120~180rpm의 속도로 70시간~74시간, 바람직하게 30℃에서 150rpm의 속도로 72시간 동안 배양하여 반응액을 합성한다. 상기 혼합비율은 광나무 추출물의 항산화 유효성분을 회수하기 위한 최적의 비율이다.The obtained microbial pellet was washed with PG buffer (50 mM phosphate pH 7.2 and 2% glycerol), and suspended in 5 ml of PG buffer (the reason for suspending is to remove foreign substances contained in the medium for culturing microorganisms in a clean state) In order to induce a reaction, and to accurately determine the concentration of glycerol in the composition). Thereafter, the suspension and the K. serrata extract are mixed {Gwangnae extract: microbial pellet: PG buffer = 1: 9-11: a weight ratio of 45-55, preferably 1: 10: 50 } and 120-180 rpm at 27-33 ° C. The reaction solution is synthesized by culturing for 70 hours to 74 hours at a rate of , preferably 72 hours at 30° C. at a rate of 150 rpm. The mixing ratio is an optimal ratio for recovering the antioxidant active ingredient of the Gwangnam extract.
나. 바이오리노베이션 반응물의 생성여부 확인.me. Check whether biorenovation reactants are generated.
바이오리노베이션 반응물(반응물)의 반응여부를 확인하는 공정을 더 포함할 수 있으며, 반응이 끝난 후 원심분리하여 상등액을 바이오리노베이션 반응물로 수거하고, 감압 농축하여 DMSO(다이메틸설폭사이드, dimethyl sulfoxide)에 용해시킨 후 HPLC(high performance liquid chromatography, 고성능 액체 크로마토그래피)로 생물전환 반응물의 생성여부를 확인한다.It may further include a step of confirming whether the biorenovation reactant (reactant) reacts. After the reaction is completed, centrifugation is performed to collect the supernatant as a biorenovation reactant, and concentrated under reduced pressure in DMSO (dimethyl sulfoxide, dimethyl sulfoxide). After dissolution, the bioconversion reaction product is checked by HPLC (high performance liquid chromatography).
다. 분리 동정.All. separation sympathy.
HPLC 결과를 바탕으로 Prep-HPLC (preparative high performance liquid chromatography, 제조용 고성능 액체 크로마토그래피)를 이용하여 생성한 바이오리노베이션 반응물에 대한 피크(peak)를 분리하였다. 분리된 시료는 HPLC를 통해 purity를 확인한 후, LC-Mass (Liquid chromatography-mass spectrometry, 액체 크로마토그래피 질량 분석기) 및 NMR (Nuclear magnetic resonance, 핵자기 공명)을 통해 동정한다(분리 동정은 일반적인 방법과 동일하므로 구체적인 설명을 생략한다). Based on the HPLC result, a peak for the biorenovation reaction product generated using Prep-HPLC (preparative high performance liquid chromatography) was separated. After confirming the purity of the separated sample through HPLC, it is identified through LC-Mass (Liquid chromatography-mass spectrometry) and NMR (Nuclear magnetic resonance) Since they are the same, a detailed description will be omitted).
4. 원심분리 및 여과.4. Centrifugation and filtration.
바이오리노베이션 반응물을 4,800~5,200rpm의 속도, 3~5℃, 8분~12분간, 바람직하게 5,000 rpm, 4℃, 10분 동안 원심분리하고, 여과지를 통해 여과한다.The biorenovation reaction is centrifuged at a speed of 4,800-5,200 rpm, 3-5° C., 8-12 minutes, preferably 5,000 rpm, 4° C., 10 minutes, and filtered through filter paper.
5. 감압 농축.5. Concentrate under reduced pressure.
여과 공정을 거친 바이오리노베이션 반응물의 유효성분 농도를 높이기 위하여 바이오리노베이션 반응물을 감압 농축(통상의 감압 농축 조건 안에서 자유롭게 실시 가능하므로 감압 농축의 조건을 구체적인 수치로 한정하지 아니한다)한다.In order to increase the concentration of the active ingredient of the biorenovation reactant that has undergone the filtration process, the biorenovation reactant is concentrated under reduced pressure (it can be freely carried out under normal reduced pressure concentration conditions, so the conditions for concentration under reduced pressure are not limited to specific values).
6. 동결 건조.6. Freeze drying.
감압 농축을 거친 농축액을 동결 건조하여 보관할 수 있으며, 동결 건조 공정은 필요에 따라 선택되는 것이다.The concentrate that has been concentrated under reduced pressure can be stored by freeze-drying, and the freeze-drying process is selected as needed.
본 발명에 의한 미백 조성물은 화장품, 외용 약품 등에 0.01~25중량%의 함량을 만족하도록 첨가되어 사용된다.The whitening composition according to the present invention is added so as to satisfy a content of 0.01 to 25% by weight in cosmetics, external drugs, and the like.
본 발명에 의한 미백 조성물의 바람직한 실시예는 다음과 같다.Preferred examples of the whitening composition according to the present invention are as follows.
<실시예><Example>
1. 제조.1. Manufacturing.
가. 광나무 추출물 : 광나무(제주특별자치도 제주시 한림읍에서 채취한 원물을 제주자원식물연구소에서 제공)의 잎 300g을 70% 에탄올(Ethanol) 1 L의 양으로 60ㅀC에서 3시간 동안 가열하여 주정추출함으로써 광나무 추출물을 제조하였다.go. Gwangnam extract: 300 g of leaves of Gwangnam (raw material collected in Hallim-eup, Jeju-si, Jeju-si, Jeju-si, Jeju Special Self-Governing Province, provided by the Jeju Resources Plant Research Institute) are heated with 1 L of 70% ethanol at 60°C for 3 hours to extract alcohol. An extract was prepared.
나. 미생물 : 미생물센터에서 분양받은 Bacillus amyloliquefaciens (KCTC 43033) 균주를 이용하여 바이오 리노베이션(Biorenovation) 반응에 사용하였으며, 균주의 증식에 필요한 Nutrient Broth (Beef extract 3.0 g/L, Peptone 5.0 g/L) 배지를 이용하여 30℃에서 150rpm의 속도로 72시간 동안 배양하였다. 이 균주를 20시간 배양 후, 5,000 rpm, 4℃, 10분 동안 원심분리하여 미생물 펠렛(pellet)을 수득하였다. 수득한 미생물 펠렛을 PG 버퍼 (50 mM phosphate pH 7.2 및 2% 글리세롤)로 세척하여, PG buffer 5ml에 현탁시켰다. me. Microorganism: Bacillus amyloliquefaciens (KCTC 43033) strain acquired from the Microbial Center was used for the biorenovation reaction, and Nutrient Broth (Beef extract 3.0 g/L, Peptone 5.0 g/L) medium required for the growth of the strain was used. and incubated for 72 hours at 30° C. at a speed of 150 rpm. After culturing this strain for 20 hours, centrifugation was performed at 5,000 rpm, 4° C., for 10 minutes to obtain a microbial pellet. The obtained microbial pellet was washed with PG buffer (50 mM phosphate pH 7.2 and 2% glycerol), and suspended in 5 ml of PG buffer.
다. 바이오리노베이션.All. biorenovation.
광나무 추출물과 미생물을 혼합한 후 30℃에서 72시간 동안 150rpm의 속도로 반응시킨 후 분리동정을 통해 바이오리노베이션 반응물의 시료를 생성하고 원심분리를 통해 상등액을 감압 농축 후 -110℃에서 동결건조하여 사용하였다.After mixing the extract and microorganisms at 30 ° C. for 72 hours at a speed of 150 rpm, a sample of the biorenovation reaction product is generated through separation and identification, and the supernatant is concentrated under reduced pressure through centrifugation and freeze-dried at -110 ° C. did.
2. 테스트.2. Test.
본 실시예의 테스트는 B16F10 melanoma 세포를 이용하여 세포 생존율, melanin 합성 저해, tyrosinase 활성 저해, 멜라닌 합성에 관여하는 TRP-1, TRP-2, MITF, tyrosinase의 단백질 발현량을 확인하는 것이다.The test of this example is to confirm the protein expression levels of TRP-1, TRP-2, MITF, and tyrosinase involved in cell viability, melanin synthesis inhibition, tyrosinase activity inhibition, and melanin synthesis using B16F10 melanoma cells.
가. 세포 배양.go. cell culture.
본 테스트에서 사용된 α-멜라닌세포 자극 호르몬 (α-MSH, α-melanocyte-stimulating hormone)과 L-3,4-dihydroxyphenylalanin (L-DOPA)는 Sigma-Aldrich Co. (St. Louis, MO, USA)에서 구입하여 사용하였다. B16F10 melanoma 세포는 ATCC사 (American Type Cell Culture, USA)에서 분양을 받았으며 10% Fetal Bovine Serum (FBS, Gibco BRL Co., Grand Island, NY, USA), 1% penicillin/streptomycin을 함유한 Dulbecco's modified Eagle's medium (DMEM, Gibco BRL Co. Grand Island, NY, USA) 배지를 사용하여 37ㅀC, 5% CO2 인큐베이터에서 배양하였으며 3일에 한 번씩 계대배양을 하였다. α-Melanocyte-stimulating hormone (α-MSH, α-melanocyte-stimulating hormone) and L-3,4-dihydroxyphenylalanin (L-DOPA) used in this test were obtained from Sigma-Aldrich Co., Ltd. (St. Louis, MO, USA) was purchased and used. B16F10 melanoma cells were purchased from ATCC (American Type Cell Culture, USA), and Dulbecco's modified Eagle's containing 10% Fetal Bovine Serum (FBS, Gibco BRL Co., Grand Island, NY, USA) and 1% penicillin/streptomycin. medium (DMEM, Gibco BRL Co. Grand Island, NY, USA) was cultured in an incubator at 37 °C, 5% CO 2 and subcultured once every 3 days.
나. 바이오리노베이션(Biorenovation) 생물전환의 HPLC 분석me. HPLC Analysis of Biorenovation Bioconversion
Shimadzu SpectroMonitor 3200 digital UV/Vis detector (Phenomenex 4 μm Hydro-RP 80 Å, 250×4.6 mm)를 이용하여 시료의 HPLC 비교 분석을 진행하였으며, 정제수(0.1% TFA (Trifluoroacetic acid))와 Acetonitrile를 이동상으로 사용하였다. 이동상의 조성은 A: H2O 99.9: TFA (Trifluoroacetic acid) 0.1, B: Acetonitrile이며 A: 90%, B: 10%로 시작하여 30 min에 A: 0%, B: 100%의 조건으로 분석하였다. 또한 최대 흡수 파장인 UV 254 nm, Ethanol에 녹인 시료 10 μl, 용매의 유속 1.0 mL/min, column 온도 40℃, Gradient 조건으로 분석하였다.HPLC comparative analysis of the sample was performed using Shimadzu SpectroMonitor 3200 digital UV/Vis detector (Phenomenex 4 μm Hydro-
도 2는 광나무 추출물(LJ)과 생물 전환된 광나무 추출물(LJBR), 바이오리노베이션(Biorenovation)에 사용된 미생물인 B. amyloliquefaciens(KCTC 43033) 추출물(BA)의 HPLC 크로마토그램의 그래프이며, HPLC로 분석한 결과 LJBR 14-17.5min 에서 LJ에 존재하지 않는 신규 peak 생성이 확인되었다. 이는 LJ에 존재하는 미지의 반응물이 미생물과의 대사작용을 통해 새로운 반응물로 전환되었을 가능성을 시사한다. Figure 2 is a graph of HPLC chromatograms of B. amyloliquefaciens (KCTC 43033) extract (BA), which is a microorganism used for biorenovation (Biorenovation), bioconverted L. japonica extract (LJ), and bioconverted L. japonica extract (LJBR). As a result, it was confirmed that a new peak that does not exist in LJ was generated at LJBR 14-17.5min. This suggests that the unknown reactant present in the LJ may have been converted into a new reactant through metabolism with microorganisms.
다. 세포생존능(Cell viability).All. Cell viability.
B16F10 melanoma 세포에 대한 광나무 추출물 (LJ)과 생물 전환된 광나무 추출물 (LJBR), Biorenovation에 사용된 B. amyloliquefaciens 추출물 (BA)의 세포 독성은 MTT assay를 통해 측정하였다. B16F10 melanoma 세포를 24 well plate에 1.0 × 10⁴ cells/well로 분주하여 37°C, 5% CO₂ 인큐베이터에서 24시간 배양한 후 α-MSH (200 nM)와 각 시료를 25, 50, 100 μg/mL의 농도로 처리하여 72시간 배양하였다.Cytotoxicity of B16F10 melanoma cells (LJ), bioconverted L. amygdala extract (LJBR), and B. amyloliquefaciens extract (BA) used for biorenovation was measured by MTT assay. B16F10 melanoma cells were seeded in a 24-well plate at 1.0 × 10⁴ cells/well and cultured for 24 hours at 37°C, 5% CO₂ incubator. Then, α-MSH (200 nM) and 25, 50, and 100 μg/mL was treated with a concentration of and cultured for 72 hours.
이후 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide, Sigma-Aldrich, St. Louis, MO, USA) 용액을 첨가하여 37°C, 5% CO₂ 인큐베이터에서 4시간 동안 반응시킨 후 상등액을 제거하고 형성된 pellet을 DMSO (dimethyl sulfoxide)를 첨가하여 용해시킨 후 96 well plate에 담아 570 nm 파장에서 spectrophotometer (Thermo Fisher Scientific, Vantaa, Finland)를 이용하여 흡광도를 측정하였다.Then, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide, Sigma-Aldrich, St. Louis, MO, USA) solution was added and incubator at 37 °C, 5% CO₂ After reacting for 4 hours, the supernatant was removed, and the formed pellet was dissolved by adding DMSO (dimethyl sulfoxide), placed in a 96 well plate, and absorbance was measured using a spectrophotometer (Thermo Fisher Scientific, Vantaa, Finland) at a wavelength of 570 nm. .
도 3에서 알 수 있듯이, BA 및 LJ와 LJBR을 25, 50, 100 μg/mL 농도로 처리한 결과 측정 농도에서 BA, LJ, LJBR 모두 약 98% 이상의 세포 생존율을 보였다. 따라서 세포 독성을 보이지 않는 25, 50, 100 μg/mL의 농도로 추후 실험을 진행하였다.As can be seen from FIG. 3 , when BA, LJ, and LJBR were treated at concentrations of 25, 50, and 100 μg/mL, BA, LJ, and LJBR showed cell viability of about 98% or more at the measured concentrations. Therefore, subsequent experiments were carried out at concentrations of 25, 50, and 100 μg/mL that do not show cytotoxicity.
라. Melanin 생성 억제 활성 평가.la. Evaluation of melanin production inhibitory activity.
LJ와 LJBR의 멜라닌 합성 억제 효능을 확인하기 위해 B16F10 melanoma 세포를 6 well plate에 4.0 × 10⁴ cells/well로 분주하여 37°C, 5% CO₂ 인큐베이터에서 24시간 배양하였고, α-MSH (200 nM)와 LJ와 LJBR을 세포 독성이 없는 농도로 함께 처리하여 72시간 동안 배양하였다. 이후 PBS (phosphate buffered saline, Sigma-Aldrich, St. Louis, MO, USA)로 세포를 세척하고 trypsin-EDTA (Gibco, Grand Island, NY, USA)를 처리하여 세포를 회수하여 1%의 protease inhibitor (Sigma-Aldrich, St. Louis, MO, USA)가 함유된 RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA)를 넣어 세포를 lysis한 후 13,000 rpm에서 40분간 원심 분리하여 pellet과 상등액을 분리하였다. 분리한 pellet에 1 N NaOH (Sigma-Aldrich, St. Louis, MO, USA)를 넣어 90°C에 1시간 동안 가열 후 spectrophotometer를 이용하여 405 nm 파장으로 흡광도를 측정하였다. To confirm the melanin synthesis inhibitory efficacy of LJ and LJBR, B16F10 melanoma cells were seeded in a 6-well plate at 4.0 × 10⁴ cells/well and cultured for 24 hours in an incubator at 37°C, 5% CO₂, α-MSH (200 nM) and LJ and LJBR were treated together at a non-cytotoxic concentration and cultured for 72 hours. After that, the cells were washed with PBS (phosphate buffered saline, Sigma-Aldrich, St. Louis, MO, USA) and treated with trypsin-EDTA (Gibco, Grand Island, NY, USA) to recover the cells and use 1% protease inhibitor ( Cells were lysed by adding RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA) containing Sigma-Aldrich, St. Louis, MO, USA), followed by centrifugation at 13,000 rpm for 40 minutes to separate the pellet and the supernatant. did. 1 N NaOH (Sigma-Aldrich, St. Louis, MO, USA) was added to the separated pellet, heated at 90 °C for 1 hour, and absorbance was measured at a wavelength of 405 nm using a spectrophotometer.
LJ와 LJBR 처리 시 멜라닌 생성에 미치는 영향을 확인한 결과, 도 4에서 보이는 것처럼, α-MSH 단독 처리 군과 비교하여 LJ 처리군은 약 18%, 18%, 19%로 미미한 멜라닌 합성 저해를 보인 반면 LJBR 처리군은 21%, 25%, 29% 멜라닌 합성 저해를 나타내었다. 이 결과는 Biorenovation 기법으로 생물 전환된 LJBR이 기존의 LJ 보다 멜라닌 합성에 대한 우수한 저해 효과를 갖는다는 것을 나타낸다.As a result of confirming the effect on melanogenesis during LJ and LJBR treatment, as shown in FIG. 4, compared to the α-MSH alone treatment group, the LJ treatment group showed slight inhibition of melanin synthesis by about 18%, 18%, and 19%, whereas The LJBR treatment group showed inhibition of melanin synthesis by 21%, 25%, and 29%. This result indicates that LJBR bioconverted by biorenovation technique has a superior inhibitory effect on melanin synthesis than conventional LJ.
마. 티로시나아제(Tyrosinase) 생성 억제 활성 평가.mind. Tyrosinase (Tyrosinase) production inhibitory activity evaluation.
Tyrosinase는 멜라닌 생성의 관여하는 효소로 이 tyrosinase의 활성을 측정하기 위해 B16F10 melanoma 세포를 6 well plate에 4.0 × 10⁴ cells/well로 분주하여 37°C, 5% CO₂ 인큐베이터에서 24시간 배양하였고, α-MSH (200 nM)와 시료를 농도별 (25, 50, 100 μg/mL)로 함께 처리하여 72시간 동안 배양하였다. 이후 trypsin-EDTA를 3분간 처리하여 세포를 회수하고 RIPA buffer (1% protease inhibitor)를 넣어 lysis한 후 13,000 rpm에서 40분간 원심 분리하여 pellet과 상등액을 분리하였다. 분리한 상등액은 BCA protein assay kit (Thermo Scientific, USA)를 이용하여 정량하였고, 0.1 M sodiumphosphate buffer (Samchum Chemical Co., Seoul, Korea)와 L-DOPA (Sigma-Aldrich, St. Louis, MO, USA)를 2 mg/mL로 만들어, 정량한 단백질과 함께 96 well plate에 첨가하여 2시간 동안 37°C에서 반응시켰다. 반응 후 spectrophotometer를 이용하여 490 nm에서 tyrosinase 활성도를 측정하였다.Tyrosinase is an enzyme involved in melanogenesis. In order to measure the activity of this tyrosinase, B16F10 melanoma cells were dispensed at 4.0 × 10⁴ cells/well in a 6-well plate and cultured at 37°C, 5% CO₂ for 24 hours in an incubator. MSH (200 nM) and samples were treated with each concentration (25, 50, 100 μg/mL) and incubated for 72 hours. Thereafter, cells were recovered by treatment with trypsin-EDTA for 3 minutes, lysed with RIPA buffer (1% protease inhibitor), and centrifuged at 13,000 rpm for 40 minutes to separate the pellet and the supernatant. The separated supernatant was quantified using a BCA protein assay kit (Thermo Scientific, USA), and 0.1 M sodiumphosphate buffer (Samchum Chemical Co., Seoul, Korea) and L-DOPA (Sigma-Aldrich, St. Louis, MO, USA) ) at 2 mg/mL, added to a 96-well plate together with the quantified protein, and reacted at 37°C for 2 hours. After the reaction, tyrosinase activity was measured at 490 nm using a spectrophotometer.
LJ와 LJBR이 멜라닌 합성 초기단계에 작용하는 Tyrosinase에 미치는 영향을 확인한 결과, 도 5에서 보이는 것처럼, α-MSH(200 nM) 단독 처리군과 비교하여 LJ 처리군은 최고농도인 100 μg/mL에서 tyrosinase 활성이 22% 억제된 반면 LJBR 처리군에서는 25, 50, 100 μg/mL 농도에서 14%, 49%, 58% 활성 억제를 보였다. 이 결과는 생물 전환 후 tyrosinase 효소에 직간접적으로 관여하는 반응물이 생성되어 tyrosinase 효소를 억제했을 가능성을 보여준다.As a result of confirming the effect of LJ and LJBR on tyrosinase acting in the initial stage of melanin synthesis, as shown in FIG. 5, compared with the α-MSH (200 nM) alone treatment group, the LJ treatment group had the highest concentration of 100 μg/mL. While tyrosinase activity was inhibited by 22%, in the LJBR-treated group, 14%, 49%, and 58% of the activity was inhibited at concentrations of 25, 50, and 100 μg/mL. This result shows the possibility that a reactant directly or indirectly involved in the tyrosinase enzyme was generated after bioconversion, thereby inhibiting the tyrosinase enzyme.
바. 웨스턴 블롯(Western Blot).bar. Western Blot.
멜라닌 합성의 중요한 단백질인 MITF, TRP-1, TRP-2, tyrosinase의 발현량을 측정하기 위해 B16F10 melanoma 세포를 6 well plate에 4.0 × 10⁴ cells/well로 분주하여 37°C, 5% CO2 인큐베이터에서 48시간 배양한 후 α-MSH (200 nM)와 LJ와 LJBR을 농도별 (25, 50, 100 ㅅg/mL)로 함께 처리하여 48시간 동안 배양하였다. 이후 배양된 세포를 PBS를 이용해 세척하고 RIPA buffer (1% protease inhibitor)를 첨가하여 lysis한 후, 13,000 rpm에서 40분간 원심 분리하여 pellet과 상등액을 분리하였다. 분리한 상등액은 BCA protein assay kit를 이용하여 정량하였고, 정량한 상등액을 10% SDS-PAGE에 전기영동한 후 poly-vinylidene difluoride (PVDF) membrane (Milipore, Burlington, MA, USA)으로 단백질을 전이시켰다. 그 후 0.05% Tween 20/Tris-buffered saline (0.05% T/ TBS)에 5% skim milk를 포함한 용액을 membrane에 넣어 상온에서 2시간 동안 blocking 한 후, 1차 antibody인 MITF, TRP-1, TRP-2, tyrosinase (Santa cruz Biotechnology, USA)를 각각 처리하여 저온 (4°C)에서 18시간 반응시켰고, 0.05% T/TBS로 10분간 4회 세척 후 Horseradish peroxidase (HRP)가 결합된 2차 andtibody인 anti-mouse IgG (Cell signaling, USA)을 0.05% T/TBS와 1 : 10,000으로 희석하여 상온에서 2시간 동안 부착시킨 뒤 0.05% T/TBS로 4회 세척하였다. 단백질은 Enhanced chemiluminescence kit (Bio-rad, USA)를 사용하여 Imaging densitometer (model GS-700, Bio-rad, USA)를 통해 결과를 측정하였다. 또한, MITF, TRP-1, TRP-2, tyrosinase 단백질 발현량을 imageJ program (NIH, Bethesda, MD, USA)을 이용하여 면적을 수치화한 뒤 그래프로 나타내었다.To measure the expression levels of MITF, TRP-1, TRP-2, and tyrosinase, which are important proteins for melanin synthesis, B16F10 melanoma cells were dispensed in a 6-well plate at 4.0 × 10⁴ cells/well, 37°C, 5% CO 2 Incubator After incubation for 48 hours, α-MSH (200 nM) and LJ and LJBR were treated together at each concentration (25, 50, 100 μg/mL) and incubated for 48 hours. Then, the cultured cells were washed with PBS, lysed by adding RIPA buffer (1% protease inhibitor), and centrifuged at 13,000 rpm for 40 minutes to separate the pellet and the supernatant. The separated supernatant was quantified using a BCA protein assay kit. After electrophoresis of the quantified supernatant on 10% SDS-PAGE, the protein was transferred to a poly-vinylidene difluoride (PVDF) membrane (Milipore, Burlington, MA, USA). . After that, a solution containing 5% skim milk in 0.05
앞선 실험 결과에서 α-MSH가 처리된 세포에 대하여 LJ 처리 시 melanin 생성이 저해된 것에 비해 도 6 내지 도 9에서 보이는 것처럼, 멜라닌 합성 관련 인자인 TRP-1, TRP-2, MITF 및 tyrosinase의 발현은 농도 의존적인 저해 활성을 보이지 않았다. 반면에 LJBR 처리군은 기존 추출물(LJ) 보다 우수하고 농도 의존적인 미백활성을 나타내었으며 특히 TRP-1 과 tyrosinase 발현은 LJBR 100 μg/mL 농도에서 각각 89%, 90% 감소하여 무처리군 보다도 우수한 미백 활성을 나타내었다. 이는 LJ가 천연소재인 특성상 소재 내 여러 성분이 다발적으로 작용하여 관련 인자들의 발현이 일관되게 나타나지 않은 것으로 판단되며 LJBR은 Biorenovation 과정에서 특정 반응물의 구조가 변화되어 특이적으로 작용되었기에 우수한 미백활성을 나타낸 것으로 사료된다.As shown in FIGS. 6 to 9, the expression of melanin synthesis-related factors, TRP-1, TRP-2, MITF and tyrosinase, compared to the results of the previous experiment where melanin production was inhibited during LJ treatment for α-MSH-treated cells. did not show concentration-dependent inhibitory activity. On the other hand, the LJBR-treated group showed superior and concentration-dependent whitening activity than the existing extract (LJ). In particular, the expression of TRP-1 and tyrosinase decreased by 89% and 90% at LJBR 100 μg/mL concentration, respectively, making it superior to the untreated group. It showed whitening activity. This is due to the fact that LJ is a natural material, and it is judged that the expression of related factors did not appear consistently due to the multiple components acting in the material. It is presumed to have been shown
상기의 테스트 결과를 정리하면, α-MSH로 자극된 B16F10 melanoma 세포에 대하여 광나무 추출물(LJ)과 바이오리노베이션(Biorenovation) 기법을 이용해 생물전환시킨 반응물(LJBR)의 미백 활성을 조사한 결과, 세포 독성을 보이지 않는 농도 (25, 50, 100 ㅅg/mL) 내에서 melanin 생성량 및 melanin 합성에 관여하는 TRP-1, TRP-2, MITF 그리고 tyrosinase의 발현을 확인한 결과 LJ와 LJBR 모두 melanin합성을 저해하였지만 LJBR에서 더 우수한 활성을 나타내었다. 또한 LJ에서는 melanin 합성 관여인자의 발현이 농도 의존적으로 저해되지 않은 반면에 LJBR 에서는 농도의존적인 저해 활성이 확인되었으며 특히 100 μg/mL 농도에서 TRP-1과 tyrosinase 발현은 무처리군과 유사한 수준으로 감소하였다. 따라서 LJBR이 멜라닌 합성과 관련된 효소 및 단백질 발현에 직간접적인 영향을 미침으로써 멜라닌 합성에 대한 저해 활성을 갖는다는 것을 확인하였으며 이 결과는 바이오리노베이션(Biorenovation)기법을 이용한 생물전환이 천연물의 생리활성 증대를 유도할 수 있음을 시사한다. Summarizing the above test results, as a result of examining the whitening activity of B16F10 melanoma cells stimulated with α-MSH, the bioconverted reactant (LJBR) using the Gwangnam tree extract (LJ) and the biorenovation technique, the cytotoxicity was determined. As a result of confirming the expression of TRP-1, TRP-2, MITF and tyrosinase involved in melanin production and melanin synthesis within invisible concentrations (25, 50, 100 g/mL), both LJ and LJBR inhibited melanin synthesis, but LJBR showed better activity. In addition, while the expression of factors involved in melanin synthesis was not inhibited in a concentration-dependent manner in LJ, a concentration-dependent inhibitory activity was confirmed in LJBR. did. Therefore, it was confirmed that LJBR has inhibitory activity on melanin synthesis by directly or indirectly affecting the expression of enzymes and proteins related to melanin synthesis. suggest that it can be induced.
Claims (6)
미생물로 바실러스 아미로리쿼파시엔스(Bacillus amyloliquefaciens)를 선정하고 배양한 후 원심분리하여 미생물 펠렛을 수득하는 제2단계와;
상기 제2단계에서 수득한 미생물 펠렛과 상기 제1단계에서 제조한 광나무 추출물을 혼합 반응시키는 제3단계를 포함하고,
상기 제1단계는 광나무의 꽃과 잎을 에탄올로 주정추출한 후 감압 농축을 통해 광나무 추출물을 추출하는 것을 특징으로 하는 광나무 추출물의 바이오리노베이션에 의한 미백 조성물의 제조 방법.A first step of preparing an extract of Gwangju;
A second step of selecting and culturing Bacillus amyloliquefaciens as a microorganism and then centrifuging to obtain a microbial pellet;
A third step of mixing and reacting the microbial pellets obtained in the second step and the Kwangnam tree extract prepared in the first step,
The first step is a method for producing a whitening composition by biorenovation of a gwang tree extract, characterized in that after extracting the flowers and leaves of gwang tree with ethanol and then extracting the gwang tree extract through concentration under reduced pressure.
[Claim 5] The method of claim 4, wherein the method for producing a whitening composition by biorenovation of a Kwangnam tree extract comprises a fourth step of centrifuging the bioconverted renovation reaction product through the third step.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200187046A KR102463782B1 (en) | 2020-12-30 | 2020-12-30 | A whitening composition and its manufacturing method by bio-renovation of Ligustrum Janponicum Extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200187046A KR102463782B1 (en) | 2020-12-30 | 2020-12-30 | A whitening composition and its manufacturing method by bio-renovation of Ligustrum Janponicum Extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220095489A KR20220095489A (en) | 2022-07-07 |
KR102463782B1 true KR102463782B1 (en) | 2022-11-04 |
Family
ID=82398583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200187046A Active KR102463782B1 (en) | 2020-12-30 | 2020-12-30 | A whitening composition and its manufacturing method by bio-renovation of Ligustrum Janponicum Extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102463782B1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100646078B1 (en) | 2004-10-20 | 2006-11-15 | 재단법인서울대학교산학협력재단 | Composition for the Prevention and Treatment of Degenerative Cranial Nerve Diseases Containing Orchard Extract |
JP2013184942A (en) | 2012-03-09 | 2013-09-19 | Kose Corp | Antioxidant and dna damage inhibitor |
KR101801223B1 (en) | 2017-03-06 | 2017-11-24 | (주)에이씨티 | Cosmetic composition containing extract of Ligustrum Lucidum as active ingredient |
KR102111648B1 (en) | 2019-08-21 | 2020-05-15 | 주식회사 인투바이오 | Method for manufacturing prunus yedoensis leaves biorenovate extract and cosmetic composition for skin whitening containing the same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101326690B1 (en) | 2007-10-31 | 2013-11-08 | (주)아모레퍼시픽 | Cosmetic composition for skin whitening containing melanin biosynthesis inhibitors from Korean ginseng |
KR100894714B1 (en) | 2007-11-09 | 2009-04-24 | 인하대학교 산학협력단 | White Wool Extract with Skin Whitening and Antioxidant Activity |
KR101081585B1 (en) * | 2009-12-08 | 2011-11-08 | (주)에이씨티 | Cosmetic composition containing extract of ligustrum japonicum and hemerocallis fulva for improving skin wrinkle |
KR102010235B1 (en) | 2019-06-07 | 2019-08-13 | 조봉상 | Cosmetic composition having skin whitening effect |
-
2020
- 2020-12-30 KR KR1020200187046A patent/KR102463782B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100646078B1 (en) | 2004-10-20 | 2006-11-15 | 재단법인서울대학교산학협력재단 | Composition for the Prevention and Treatment of Degenerative Cranial Nerve Diseases Containing Orchard Extract |
JP2013184942A (en) | 2012-03-09 | 2013-09-19 | Kose Corp | Antioxidant and dna damage inhibitor |
KR101801223B1 (en) | 2017-03-06 | 2017-11-24 | (주)에이씨티 | Cosmetic composition containing extract of Ligustrum Lucidum as active ingredient |
KR102111648B1 (en) | 2019-08-21 | 2020-05-15 | 주식회사 인투바이오 | Method for manufacturing prunus yedoensis leaves biorenovate extract and cosmetic composition for skin whitening containing the same |
Non-Patent Citations (2)
Title |
---|
문지영 외 10명. 제주도 자생식물들에 대한 미백 및 항산화 효능 탐색. J. Soc. Cosmet. Scientists Korea, 9월 2006년 |
백승오. 광나무로부터 생리활성 성분의 탐색. 한국해양대학교 대학원 학위논문, 2015.08월 |
Also Published As
Publication number | Publication date |
---|---|
KR20220095489A (en) | 2022-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101774414B1 (en) | Composition for improving skin condition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
TWI555537B (en) | Use of 3'-hydroxygenistein for manufacturing composition to inhibit melanogenesis | |
IL227447A (en) | Plant extracts comprising monoterpene derivatives of chalcone or dihydrochalcone and their use as depigmenting agents | |
KR100586814B1 (en) | Terane compounds having melanin biosynthesis inhibitory activity and preparation method thereof | |
KR101511308B1 (en) | A composite comprising red ginseng residue and ligustri fructuse for skin whitening | |
KR100907685B1 (en) | Cosmetic composition for skin whitening containing phenolic compound isolated from labor root as an active ingredient | |
KR102463782B1 (en) | A whitening composition and its manufacturing method by bio-renovation of Ligustrum Janponicum Extract | |
KR101047588B1 (en) | Whitening composition comprising white rice extract and novel pregnan compound isolated therefrom as active ingredient | |
KR102509273B1 (en) | A whitening composition and its manufacturing method by bio-renovation of Rape flower Extract | |
KR102211942B1 (en) | Cosmetic composition for whitening skin comprising extract of Sorbus aucuparia berry or fermented product of Sorbus aucuparia berry | |
KR102481735B1 (en) | A whitening composition and its manufacturing method by bio-renovation of Phryma leptostachya callus | |
KR102023571B1 (en) | Cosmetic compositions for skin whitening comprising Tenebrio molitor extracts as an active ingredient | |
KR102325393B1 (en) | Skin whitening cosmetic composition with bioconversion of Breea segeta extract | |
KR20220155224A (en) | Composition for skin whitening comprising nanovesicles | |
Park et al. | Effects of phenolics from Oplismenus undulatifolius in α-MSH-stimulated B16F10 melanoma cells | |
KR20130123490A (en) | Cosmetic composition comprising maackia amurensis extract for skin whitening | |
KR20220129921A (en) | Whitening composition by microbial bioconversion of quince leaf extract and method for preparing the same | |
KR102054132B1 (en) | Composition comprising extract of Prasiola japonica for skin whitening | |
Yang et al. | Extraction and separation of sinapine from rapeseed cake and the mode of action of melanin production inhibition | |
Lee et al. | Melanin synthesis inhibition and radical scavenging activities of compounds isolated from the aerial part of Lespedeza cyrtobotrya | |
KR102642545B1 (en) | Composition for improving skin wrinkles and elasticity containing fermented ginseng sprouts as an active ingredient | |
KR102789270B1 (en) | Cosmetic composition containing fermented extracts of Mallotus japonicus and Connarus semidecandrus probiotic with increased bergenin content for skin tone improvement and energy boosting | |
KR102683158B1 (en) | Manufacturing method of high-speed fermented sesame with enhanced content of episesaminone diglucoside and sesaminol diglucoside | |
KR102820889B1 (en) | Antioxidant, skin whitening or anti-wrinkle composition containing mixture of fermentation extract from Pinus koraiensis by-product | |
Shamu et al. | Mushroom tyrosinase inhibition and antimelanogenesis activities of Bacopa monnieri (L.) methanol extract in B16F10 melanoma cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20201230 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220822 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20221027 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20221101 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20221101 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration |